Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Circulation|July 28, 2010
Differences between out-of-hospital cardiac arrest in residential and public locations and implications for public-access defibrillationFredrik Folke, Gunnar H Gislason, Freddy K Lippert, et al.
Circulation|July 25, 2007
Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomesGunnar H Gislason, Jeppe N Rasmussen, Steen Z Abildstrom, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trialsSubodh Verma, Darren K McGuire, Stephen C Bain, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|February 9, 2008
Atrial fibrillation pharmacotherapy after hospital discharge between 1995 and 2004: a shift towards beta-blockersMorten Lock Hansen, Niels Gadsbøll, Gunnar H Gislason, et al.
Circulation|July 29, 2009
Location of cardiac arrest in a city center: strategic placement of automated external defibrillators in public locationsFredrik Folke, Freddy Knudsen Lippert, Søren Loumann Nielsen, et al.
JAMA Cardiology|December 23, 2025
Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease: An Exploratory Analysis of the SELECT Randomized Clinical TrialStephen J Nicholls, Donna H Ryan, John Deanfield, et al.
Journal of the American College of Cardiology|September 1, 2024
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF ProgramSubodh Verma, Javed Butler, Barry A Borlaug, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Diabetes Care|July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary AnalysisPeter Rossing, George Bakris, Vlado Perkovic, et al.
Circulation|December 20, 2018
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or StrokeSubodh Verma, Neil R Poulter, Deepak L Bhatt, et al.
Pageof 11